Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study.

Caterina LapucciJessica FrauEleonora CoccoGiancarlo CogheMaria PetraccaRoberta LanzilloVincenzo Brescia MorraCarolina Gabri NicolettiDoriana LandiGirolama MarfiaMarco VercellinoPaola CavallaAssunta BiancoMassimiliano MirabellaValentina Torri ClericiEugenia TomasMaria Teresa FerròPaola GrossiAgostino NozzolilloMoiola LMauro ZaffaroniMarco RonzoniFederica PinardiGiovanni NoviMaria CellerinoAntonio UccelliMatilde Inglese

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)

OCR after two ALM courses seemed to be safe and effective. Early IgM hypogammaglobulinemia occurred in a high proportion of patients. The evidence of inflammatory activity between ALM courses seemed to increase the risk of MS re-activation on OCR treatment.

Keyphrases

disease activity
rheumatoid arthritis
systemic lupus erythematosus
mass spectrometry
multiple sclerosis
ms ms
end stage renal disease
newly diagnosed
ejection fraction
ankylosing spondylitis
prognostic factors
juvenile idiopathic arthritis